Early Ivermectin Does Not Reduce Hospital Admission in COVID-19
Also no decrease seen in prolonged ED visits for patients with COVID-19 symptoms for up to seven days, at least one risk factor for progression
BNT162b2 Prevents Critical COVID-19 in Children and Adolescents
During omicron-predominant period, effectiveness of two doses against hospitalization 68 percent for children, 40 percent for adolescents
Commercial-to-Medicare Hospital Price Ratios Stable 2012 to 2019
Trends in ratios varied considerably across hospital referral regions
Physician’s Briefing Weekly Coronavirus Roundup
Health, Economic Impact of COVID-19 Set to Lessen in Coming Years
Health care use projected to normalize after decline in 2020; remaining federal supplemental spending expected to decrease through 2024
Higher Incidence of SARS-CoV-2 Infection in Under 5s During Omicron
Higher incidence rate of infection compared with delta variant, but significantly lower risk of severe clinical outcomes
Early Use of COVID-19 Convalescent Plasma Cuts Hospitalization Risk
Administration of convalescent plasma within nine days after symptom onset can reduce risk of COVID-19-linked hospitalization
Eight-Gene Model Can Help Predict Progression to Severe Dengue
Model predicted severe dengue progression with 86.4 percent sensitivity and 79.7 percent specificity
Risk for Acute MI Not Increased With Two-Dose HepB-CpG Vaccine
Noninferiority study shows no increased risk for acute MI with two-dose HepB-CpG vaccine versus three-dose HepB-alum vaccine
Universal HepB Vaccination Recommended for Adults Age 19 to 59
Those aged 60 years or older with risk factors should receive vaccine; those without risk factors should be offered vaccine
